P. Crawford, M. Feely, A. Guberman, and G. Kramer, Are there potential problems with generic substitution of antiepileptic drugs?, Seizure, vol.15, issue.3, pp.165-76, 2006.
DOI : 10.1016/j.seizure.2005.12.010

F. Besag, Generic antiepileptic drugs and increased health care utilization: Fact or myth?, Neurology, vol.74, issue.20, pp.1562-1565, 2010.
DOI : 10.1212/WNL.0b013e3181e1d4b4

D. Heaney and J. Sander, Antiepileptic drugs: generic versus branded treatments, The Lancet Neurology, vol.6, issue.5, pp.465-473, 2007.
DOI : 10.1016/S1474-4422(07)70105-9

M. Bialer, Generic Products of Antiepileptic Drugs (AEDs): Is It an Issue?, Epilepsia, vol.30, issue.10, pp.1825-1857, 2007.
DOI : 10.1016/j.yebeh.2004.05.011

G. Krämer, A. Biraben, M. Carreno, A. Guekht, G. De-haan et al., Current approaches to the use of generic antiepileptic drugs, Epilepsy & Behavior, vol.11, issue.1, pp.46-52, 2007.
DOI : 10.1016/j.yebeh.2007.03.014

K. Liow, G. Barkley, J. Pollard, C. Harden, and C. Bazil, Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy, Neurology, vol.68, issue.16, pp.1249-50, 2007.
DOI : 10.1212/01.wnl.0000259400.30539.cc

E. Perucca, F. Albani, G. Capovilla, B. Bernardina, R. Michelucci et al., Recommendations of the Italian League Against Epilepsy Working Group on Generic Products of Antiepileptic Drugs, Epilepsia, vol.26, issue.5, pp.16-20, 2006.
DOI : 10.1001/jama.258.9.1216

A. Biraben, B. De-toffol, F. Semah, and T. Rouault, Utilisation des m??dicaments g??n??riques des anti-??pileptiques en France : r??sultats d???une enqu??te aupr??s des neurologues et revue de la litt??rature, Revue Neurologique, vol.163, issue.4, pp.455-61, 2007.
DOI : 10.1016/S0035-3787(07)90421-X

M. Berg, R. Gross, L. Haskins, W. Zingaro, and K. Tomaszewski, Generic substitution in the treatment of epilepsy: Patient and physician perceptions, Epilepsy & Behavior, vol.13, issue.4, pp.693-702, 2008.
DOI : 10.1016/j.yebeh.2008.06.001

K. Hensler, C. Uhlmann, T. Porschen, R. Benecke, and J. Rösche, Generic substitution of antiepileptic drugs ??? A survey of patients' perspectives in Germany and other German-speaking countries, Epilepsy & Behavior, vol.27, issue.1, pp.135-144, 2013.
DOI : 10.1016/j.yebeh.2012.12.029

S. Ngo, I. Stupans, and R. Mckinnon, Generic substitution in the treatment of epilepsy: Patient attitudes and perceptions, Epilepsy & Behavior, vol.26, issue.1, pp.64-70, 2013.
DOI : 10.1016/j.yebeh.2012.10.032

F. Andermann, M. Duh, A. Gosselin, and P. Paradis, Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug Classes, Epilepsia, vol.26, issue.3, pp.464-473, 2007.
DOI : 10.1001/jama.258.9.1216

J. Lelorier, M. Duh, P. Paradis, P. Lefebvre, J. Weiner et al., Clinical consequences of generic substitution of lamotrigine for patients with epilepsy, Neurology, vol.70, issue.Issue 22, Part 2, pp.2179-86, 2008.
DOI : 10.1212/01.wnl.0000313154.55518.25

M. Duh, P. Paradis, D. Latrémouille-viau, P. Greenberg, S. Lee et al., The risks and costs of multiple-generic substitution of topiramate, Neurology, vol.72, issue.24, pp.2122-2131, 2009.
DOI : 10.1212/WNL.0b013e3181aa5300

D. Labiner, P. Paradis, R. Manjunath, M. Duh, M. Lafeuille et al., Generic antiepileptic drugs and associated medical resource utilization in the United States, Neurology, vol.74, issue.20, pp.1566-74, 2010.
DOI : 10.1212/WNL.0b013e3181df091b

W. Zachry, Q. Doan, J. Clewell, and B. Smith, Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes, Epilepsia, vol.5, issue.Suppl 5, pp.493-500, 2009.
DOI : 10.1111/j.1528-1167.2008.01703.x

R. Hansen, J. Campbell, and S. Sullivan, Association between antiepileptic drug switching and epilepsy-related events, Epilepsy & Behavior, vol.15, issue.4, pp.481-486, 2009.
DOI : 10.1016/j.yebeh.2009.05.019

K. Rascati, K. Richards, M. Johnsrud, and T. Mann, Effects of Antiepileptic Drug Substitutions on Epileptic Events Requiring Acute Care, Pharmacotherapy, vol.41, issue.7, pp.769-74, 2009.
DOI : 10.1111/j.1528-1167.2008.01703.x

A. Kesselheim, M. Stedman, E. Bubrick, J. Gagne, A. Misono et al., Seizure Outcomes Following the Use of Generic versus Brand-Name Antiepileptic Drugs, Drugs, vol.14, issue.1, pp.605-626, 2010.
DOI : 10.2165/10898530-000000000-00000

S. Erickson, L. Le, S. Ramsey, B. Solow, A. Zakharyan et al., Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy, Epilepsia, vol.50, issue.7, pp.1365-71, 2011.
DOI : 10.1111/j.1528-1167.2011.03130.x

N. Shcherbakova, K. Rascati, C. Brown, K. Lawson, S. Novak et al., Factors Associated with Seizure Recurrence in Epilepsy Patients Treated with Antiepileptic Monotherapy: A Retrospective Observational Cohort Study using US Administrative Insurance Claims, CNS Drugs, vol.58, issue.1???2, pp.1047-58, 2014.
DOI : 10.1007/s40263-014-0191-1

S. Devine, E. Weisbart, J. Barron, and A. Behm, Acute epilepsy exacerbations in patients switched between A-rated anti-epileptic drugs, Current Medical Research and Opinion, vol.26, issue.2, pp.455-63, 2010.
DOI : 10.1185/03007990903488704

R. Hansen, H. Nguyen, and S. Sullivan, Bioequivalent antiepileptic drug switching and the risk of seizure-related events, Epilepsy Research, vol.106, issue.1-2, pp.237-280, 2013.
DOI : 10.1016/j.eplepsyres.2013.04.010